Ras Al Khaimah, United Arab Emirates-Thursday, June 8th 2017 [ ME NewsWire ]
Marketed in tablets form, Dandasha (Tadalafil 20 mg) is an inhibitor of phosphodiesterase type 5 (PDE5), which mediates relaxation of vascular smooth muscle in particular areas of the body, facilitating and maintaining erection for up to 36 hours.
Commenting on the launch of Dandasha, Julphar’s Marketing Director Dr Hosam Badr said: “Julphar has been active in many major therapeutic segments. ED is the 8th biggest segment in the UAE pharmaceutical market, with a market size estimated at AED 165 million and a common problem affecting 52% of men worldwide. We have been considering entering this segment for a while and with the launch of Dandasha, we are moving one step closer to our mission to improve our patients’ quality of life.”
“Dandasha is expected to become one of Julphar’s major brands in the UAE and lead the company’s growth in the upcoming years. Our plan in the near future is to launch Dandasha in the Middle East and North Africa (MENA) region and bring additional men’s health-related drugs to the market,” he added.
Established in 1980, Julphar is the largest generic pharmaceutical manufacturer in Middle East and North Africa, producing over 200 branded products across 15 facilities. Julphar’s mission is to offer high quality medicines at affordable prices. Our product portfolio includes Biotechnology, Wound and Women Care, Adult and Pediatric General Medicines, Gastro and Pain Management, Cardio-Metabolism, Diabetes and Consumer range. Julphar employs more than 3,000 people around the world and registered revenue of AED 1.45 billion in 2016. For more information, please visit http://www.julphar.net.
Corporate Communication Manager
Permalink : http://me-newswire.net/news/4043/en